Cargando…

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis

GLP-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors (SGLT2i) have been associated with improved glycemic control, body weight loss and favorable changes in cardiovascular risk factors and outcomes. We conducted a systematic review and meta-analysis to evaluate the effects of the addition of GLP-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castellana, Marco, Cignarelli, Angelo, Brescia, Francesco, Perrini, Sebastio, Natalicchio, Annalisa, Laviola, Luigi, Giorgino, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920368/ https://www.ncbi.nlm.nih.gov/pubmed/31852920 http://dx.doi.org/10.1038/s41598-019-55524-w

Ejemplares similares

Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
por: Caruso, Irene, et al.
Publicado: (2022)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Effects of CPAP on Testosterone Levels in Patients With Obstructive Sleep Apnea: A Meta-Analysis Study
por: Cignarelli, Angelo, et al.
Publicado: (2019)

Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis
por: Castellana, Marco, et al.
Publicado: (2020)

Insulin and Insulin Receptors in Adipose Tissue Development
por: Cignarelli, Angelo, et al.
Publicado: (2019)

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
por: Caruso, Irene, et al.
Publicado: (2023)

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity
por: Marrano, Nicola, et al.
Publicado: (2021)

Diabetes in the Time of COVID-19: A Twitter-Based Sentiment Analysis
por: Cignarelli, Angelo, et al.
Publicado: (2020)

The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor
por: D'Oria, Rossella, et al.
Publicado: (2020)

Effects of Extra Virgin Olive Oil Polyphenols on Beta-Cell Function and Survival
por: Marrano, Nicola, et al.
Publicado: (2021)

Cross-Talk between PPARγ and Insulin Signaling and Modulation of Insulin Sensitivity
por: Leonardini, Anna, et al.
Publicado: (2009)

Role of Glucose-Lowering Medications in Erectile Dysfunction
por: Cignarelli, Angelo, et al.
Publicado: (2021)

Impaired Leptin Signalling in Obesity: Is Leptin a New Thermolipokine?
por: Genchi, Valentina Annamaria, et al.
Publicado: (2021)

Differences in Gene Expression and Cytokine Release Profiles Highlight the Heterogeneity of Distinct Subsets of Adipose Tissue-Derived Stem Cells in the Subcutaneous and Visceral Adipose Tissue in Humans
por: Perrini, Sebastio, et al.
Publicado: (2013)

Implicazioni cliniche extraglicemiche dell’insulino-resistenza
por: Caporusso, Mariangela, et al.
Publicado: (2022)

Hepatokines, bile acids and ketone bodies are novel Hormones regulating energy homeostasis
por: Garruti, Gabriella, et al.
Publicado: (2023)

TNFα Signals via p66(Shc) to Induce E-Selectin, Promote Leukocyte Transmigration and Enhance Permeability in Human Endothelial Cells
por: Laviola, Luigi, et al.
Publicado: (2013)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
por: Baviera, Marta, et al.
Publicado: (2022)

Type 2 Diabetes and Alzheimer’s Disease: The Emerging Role of Cellular Lipotoxicity
por: Marrano, Nicola, et al.
Publicado: (2023)

A telemedicine-based approach with real-time transmission of blood glucose data improves metabolic control in insulin-treated diabetes: the DIAMONDS randomized clinical trial
por: Di Molfetta, S., et al.
Publicado: (2022)

Postprandial glucose and HbA1c are associated with severity of obstructive sleep apnoea in non-diabetic obese subjects
por: Cignarelli, A., et al.
Publicado: (2021)

Influence of CAG Repeat Polymorphism on the Targets of Testosterone Action
por: Tirabassi, Giacomo, et al.
Publicado: (2015)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
por: Li, Chen, et al.
Publicado: (2022)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials
por: Giorgino, Francesco, et al.
Publicado: (2013)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Lee, Heeyoung, et al.
Publicado: (2021)

Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
por: Genchi, V. A., et al.
Publicado: (2023)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
por: Winiarska, Agata, et al.
Publicado: (2021)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e040ka3ea7fb40v5t68crmrqmr